Sangamo Biosciences reported $94.57M in Cash and Equivalent for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cash And Equivalent Change
Alnylam Pharmaceuticals ALNY:US USD 1.07B 497.67M
Amgen AMGN:US USD 9.5B 4.3B
Avrobio Inc AVRO:US USD 115.97M 16.44M
Bayer BAYN:GR EUR 4.36B 949M
Biocryst Pharmaceuticals BCRX:US USD 461.19M 43.71M
Biogen BIIB:US USD 3.68B 1.03B
Biomarin Pharmaceutical BMRN:US USD 761.52M 141.71M
Bluebird Bio BLUE:US USD 66.48M 15.02M
Gilead Sciences GILD:US USD 6.94B 2.2B
GlaxoSmithKline GSK:LN GBP 3.61B 2.86B
Intercept Pharmaceuticals ICPT:US USD 113.2M 55.18M
IONIS PHARMACEUT IONS:US USD 314.99M 206.92M
Karyopharm Therapeutics KPTI:US USD 71.35M 10.9M
Novartis NOVN:VX USD 8.73B 5.1B
Omeros OMER:US USD 145.53M 131.4M
Regulus Therapeutics RGLS:US USD 20.01M 15.1M
Sangamo Biosciences SGMO:US USD 94.57M 23.14M
Sarepta Therapeutics SRPT:US USD 1.04B 170.06M
Ultragenyx Pharmaceutical RARE:US USD 391.65M 231.78M
Vertex Pharmaceuticals VRTX:US USD 9.17B 469.3M
Ziopharm Oncology ZIOP:US USD 37.81M 22.2M